Paul Gross

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Datalogix Holdings, Inc. provides database marketing and digital media solutions. It offers core infrastructure for data-driven marketing by connecting digital advertising to offline sales. The firm serves the retail, automotive, consumer packaged goods, and financial sectors. The company was founded by Robert W. Gierkink and Tim Wright in 2002 and is headquartered in Westminster, CO.

Cooley LLP engages in the provision of legal services. It offers strategic litigation and business transaction services and is a representative of private and public companies, financial institutions, venture capital firms and nonprofit organizations. Its practices include commercial litigation; patent counseling and prosecution; employment and labor; asset recovery; and estate planning and personal representation. The company was founded in 1920 and is headquartered in New York, NY.

Part of Clovis Oncology, Inc., Clovis Oncology UK Ltd. is a company that engages in research and development on biotechnology. Clovis Oncology UK Ltd. is based in Cambridge, UK.